rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Tonix Pharmaceuticals Holding Corp.

TNXP · Nasdaq

Health CareBiotechnologyNot moving yet

TNXP stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 50.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$918K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
101 (+22)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$552KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months7
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Seth LedermanChief Executive Officerbought2,000at $13.7927 Aug 2026filed 31 Aug 2026
Richard H. BaggerDirectorbought1,000at $12.6020 Aug 2026filed 24 Aug 2026
Carolyn E. TaylorDirectorbought1,415at $10.5512 Jun 2026filed 15 Jun 2026
Seth LedermanChief Executive Officerbought5,000at $11.799 Jun 2026filed 9 Jun 2026
Richard Newcomb StillwellDirectorbought5,000at $11.658 Jun 2026filed 9 Jun 2026
Seth LedermanChief Executive Officerbought5,000at $12.6231 Mar 2026filed 1 Apr 2026
Seth LedermanChief Executive Officerbought15,000at $14.8918 Mar 2026filed 18 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders101+22 on the quarter
New · exited30 · 7
Reported value$119.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20261,398,041$17.8M+429,864+44.4%
Point72 Asset Management, L.P.added · filed 14 Aug 20261,166,752$14.9M+1,041,338+830.3%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 2026966,932$12.3M+747,259+340.2%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026882,595$11.3M+721,387+447.5%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026691,895$8.8M+173,245+33.4%
Jones Hill Capital LPadded · filed 13 Aug 2026625,428$8.0M+173,312+38.3%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026395,260$5.0M+81,969+26.2%
Ishara Investments LPnew · filed 14 Aug 2026338,250$4.3M+338,250
STATE STREET CORPadded · filed 7 Aug 2026271,374$3.5M+40,767+17.7%
UBS Group AGadded · filed 13 Aug 2026231,682$3.0M+40.0%
30 Jun 2023 – 30 Jun 2026
216098Jun 23Mar 24Dec 24Sep 25Jun 26

Everyone who traded it

Seth Lederman Company insiderChief Executive Officer · last 27 Aug 202645 · 0
Richard H. Bagger Company insiderDirector · last 20 Aug 20262 · 0
Bradley Saenger Company insiderChief Financial Officer · last 30 Jun 20262 · 0
Carolyn E. Taylor Company insiderDirector · last 12 Jun 20262 · 0
Richard Newcomb Stillwell Company insiderDirector · last 8 Jun 20261 · 0
Adeoye Y. Olukotun Company insiderDirector · last 12 May 20261 · 0
David L. Grange Company insiderDirector · last 12 May 20260 · 0
James Randolph Hunter Jr. Company insiderDirector · last 12 May 20260 · 0
James Treco Company insiderDirector · last 12 May 20263 · 0
Margaret Smith Bell Company insiderDirector · last 12 May 20261 · 0
Gregory M. Sullivan Company insiderChief Medical Officer · last 24 Feb 20268 · 0
Jessica Edgar Morris Company insiderChief Operating Officer · last 24 Feb 20261 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202549.3%
Operating profit marginFY 2025 · to 31 Dec 2025-959%
Free cash flow marginFY 2025 · to 31 Dec 2025-787%
Return on capital employedFY 2025 · to 31 Dec 2025-51.0%
Research spendFY 2025 · to 31 Dec 2025339%
Share count trendFY 2025 · to 11 Mar 20264.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$207.6M
Free cash flowFY 2025 · to 31 Dec 2025−$103.2M

Analyst forecasts

No analyst forecasts yet.